Tasosartan
| |
Clinical data | |
---|---|
Pregnancy category |
|
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C23H21N7O |
Molar mass | 411.459 g/mol |
|
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.